# Problem
Problem 4. [Identification of Next-Generation Targets and Delivery Strategies to Enhance Antibody Transport Across the Blood–Brain Barrier (BBB)]


Background
One of the most significant technological challenges in the treatment of central nervous system (CNS) diseases is the Blood–Brain Barrier (BBB). The BBB severely restricts the entry of large molecules, and as a result, most antibodies and biologic therapeutics fail to achieve effective brain exposure.
Recent advances have explored strategies such as receptor-mediated transcytosis (RMT) to enhance BBB penetration, leveraging endogenous transport mechanisms. Several targets—most notably Transferrin Receptor (TfR), CD98hc (SLC3A2), and IGF1R—have been extensively studied as BBB shuttle targets. However, these approaches face important limitations related to efficiency, specificity, safety, and translational feasibility.
In this problem, you are asked to analyze existing BBB transport strategies and propose next-generation targets and antibody-based delivery approaches that could enable more effective CNS drug delivery.

Task
Based on existing literature and publicly available data, perform a comparative analysis of established BBB shuttle targets and propose two novel or emerging BBB transport targets or delivery approaches that are most promising for next-generation CNS therapeutics.
1) Analysis of Established BBB Transport Targets
Analyze the mechanisms and characteristics of representative BBB shuttle targets, including:
•	Transferrin Receptor (TfR)
•	CD98hc (SLC3A2)
•	IGF1R
Your analysis should include:
•	BBB transport mechanisms (e.g., receptor-mediated transcytosis)
•	Reported antibody- or ligand-based shuttle strategies
•	Known limitations, such as:
o	Limited brain exposure
o	Peripheral tissue expression and off-target effects
o	Safety concerns or functional perturbation
o	Challenges in affinity tuning or format optimization

2) Selection of Next-Generation BBB Transport Targets and Delivery Strategies
Excluding TfR, IGF1R, and CD98hc, propose two alternative BBB transport targets or approaches that you consider most promising for next-generation CNS drug delivery.
For each proposed target, compare it against established targets in terms of:
•	Efficiency
o	Expected increase in brain exposure or CNS delivery efficiency
•	Selectivity and Safety
o	Expression pattern in peripheral tissues
o	Risk of disrupting endogenous physiological functions
•	Translational Feasibility
o	Need for antibody affinity tuning
o	Species cross-reactivity (preclinical to clinical translation)
o	Manufacturability and format complexity

3) Antibody-Based Drug Delivery Strategy Design
For the selected targets, propose a drug delivery strategy, considering:
•	Antibody shuttle formats
o	Monospecific vs bispecific antibodies
•	Binding affinity strategies
o	Low-affinity vs high-affinity binding
o	Monovalent vs bivalent engagement
•	Payload considerations (optional)
Clearly explain how your proposed strategy addresses the limitations of existing BBB shuttle approaches.
 


# Original Answer
Problem 4. Identification of Next-Generation Targets and Delivery Strategies to Enhance Antibody Transport Across the Blood–Brain Barrier (BBB)

---

## 1) Analysis of Established BBB Transport Targets

### Common BBB transport mechanism leveraged by antibody shuttles (context)
- **Receptor-mediated transcytosis (RMT)**: (i) luminal binding → (ii) endocytosis (often clathrin-mediated) → (iii) endosomal sorting → (iv) abluminal exocytosis.
- **Key design constraint**: intracellular sorting fate. Strong/bivalent binding can bias trafficking toward **late endosome/lysosome** (degradation/trapping) rather than **recycling/transcytotic routes**, so **affinity, valency, epitope, and pH-dependent dissociation** often determine whether a shuttle is productive.

---

### A. Transferrin Receptor (TfR)
**BBB transport mechanism**
- Endogenous role: iron uptake via transferrin.
- **RMT**: TfR binding at luminal surface, internalization; **pH-dependent dissociation** in endosomes is important for productive trafficking/release.

**Reported antibody/ligand shuttle strategies**
- Early: **bivalent high-affinity anti-TfR IgGs**.
- Evolved best practice: **monovalent, reduced-affinity TfR engagement** (often via **bispecific** constructs that fuse an anti-TfR arm/domain to a therapeutic antibody).
  - Example described in the provided evidence: **trontinemab** uses a **low-affinity (~131 nM) monovalent TfR binding** module to enhance delivery of an anti-amyloid payload.

**Known limitations**
- **Limited brain exposure / sorting penalty**: high-affinity **bivalent** binding can crosslink TfR and promote **lysosomal routing**, reducing true transcytosis efficiency.
- **Peripheral expression / sink & off-targets**: TfR1 is abundant beyond BBB (notably erythroid lineage, liver, GI), creating:
  - peripheral “sink” reducing delivery efficiency
  - risk of perturbing iron handling
- **Safety concerns**: potential disruption of iron homeostasis and erythroid cell biology (especially with chronic/high dosing).
- **Affinity/format optimization challenge**: requires a narrow operating window (affinity/valency/pH dependence) to avoid trapping while maintaining BBB engagement.
- **Translational feasibility**: species cross-reactivity can be difficult; human translation has required specialized approaches (e.g., transgenic/humanized receptor systems in discovery).

---

### B. CD98hc (SLC3A2)
**BBB transport mechanism**
- CD98hc is the heavy chain subunit of heterodimeric amino acid transporters (e.g., LAT1 complex).
- Uses **endocytosis and trafficking compatible with RMT**, but with kinetics distinct from TfR.

**Reported antibody shuttle strategies**
- **Bispecific anti-CD98hc shuttles** delivering full IgG payloads have been reported.
- Notably, unlike TfR, **bivalent engagement has been reported as permissive** in some CD98hc shuttle implementations (i.e., not universally penalized by lysosomal trapping in the same way as TfR).

**Known limitations**
- **Peripheral expression**: broader than ideal (reported in lung, spleen, kidney, GI), creating off-target exposure concerns.
- **Safety/physiology risk**: potential to perturb amino acid transporter function; chronic consequences are **not fully characterized** in the provided evidence (key limitation).
- **Optimization complexity**: affinity-dose relationships appear different from TfR (e.g., affinity can help at tracer doses), which adds design degrees of freedom but also increases empirical optimization needs.
- **Kinetic behavior**: advantage is **prolonged brain retention** (reported sustained levels out to ~21 days post-dose in the provided evidence), which can be beneficial therapeutically but also implies prolonged systemic exposure requiring careful safety evaluation.

---

### C. IGF1R
**BBB transport mechanism**
- IGF1R is a receptor tyrosine kinase; internalization can occur via clathrin and non-clathrin routes.
- Antibody shuttles exploit **IGF1R-mediated internalization/transcytosis**.

**Reported antibody shuttle strategies**
- **Single-domain antibody (VHH)-based IGF1R shuttles** have been reported to deliver active neuropeptide payloads with demonstrated pharmacology in vivo.
- A key reported design feature: an IGF1R-binding epitope **distinct from the endogenous ligand binding site**, reducing risk of agonism/competition.

**Known limitations**
- **Safety/biology risk**: IGF signaling has broad roles (growth/metabolism); even if ligand-competitive effects are minimized, chronic engagement could still carry risk depending on tissue distribution and dosing.
- **Peripheral expression**: present in multiple tissues; off-target exposure is a concern.
- **Translational feasibility**: species cross-reactivity/epitope conservation can be challenging, often requiring surrogate binders across species (as described in the provided evidence).
- **Quantification gap**: while parenchymal delivery is supported, the provided evidence indicates less extensive standardized quantitative benchmarking vs TfR/CD98hc.

---

## 2) Selection of Next-Generation BBB Transport Targets and Delivery Strategies (excluding TfR, IGF1R, CD98hc)

Selected two most promising (based on the provided evidence summary):  
1. **Neonatal Fc receptor (FcRn)-mediated BBB transcytosis via Fc engineering**  
2. **Basigin (CD147)-targeted RMT (bispecific shuttle)**

### 2.1 Candidate 1: FcRn-mediated BBB transcytosis (Fc-engineered IgG)

**Efficiency (expected CNS delivery)**
- Reported in the provided evidence: Fc variants that increase **neutral pH FcRn binding** can yield **~40–80× improvement in brain:serum ratio** (relative to WT IgG), with some in vitro BBB model reports indicating much larger fold-changes (up to ~150× in that context).
- This directly targets a major limitation of standard IgGs (typically <1% brain penetration), aiming to raise partitioning into a more therapeutically actionable range.

**Selectivity and Safety**
- **Expression pattern**: FcRn is widespread (systemic endothelium and other tissues). Therefore:
  - BBB selectivity is not driven by receptor localization alone.
  - Risk is more about **system-wide altered IgG handling/transcytosis and PK** than about a single peripheral “sink” tissue.
- **Physiology disruption risk**: FcRn is central to IgG homeostasis; Fc engineering must avoid excessive perturbation of recycling/half-life.
  - The provided evidence indicates Fc variants can increase BBB transport but may also change clearance; this is a key tradeoff to manage.

**Translational feasibility**
- **Affinity tuning need**: yes, but **at the Fc–FcRn interface**, typically as a manageable variant screening/selection problem rather than dual-arm bispecific balancing.
- **Species cross-reactivity**: strong overall feasibility because FcRn biology is conserved and Fc engineering can be evaluated across rodent and non-human primate systems.
- **Manufacturability/format complexity**: **low**—remains a standard monoclonal antibody architecture (no bispecific assembly required).

---

### 2.2 Candidate 2: Basigin (CD147)-targeted RMT (bispecific BBB shuttle)

**Efficiency (expected CNS delivery)**
- Reported in the provided evidence: proof-of-concept supports BBB transcytosis/internalization; however, **quantitative performance is less mature** than TfR/CD98hc.
- The provided evidence summarizes an estimated **~1–4× improvement** vs non-targeted controls in available datasets, with clear acknowledgment that deeper characterization is needed (knowledge gap).

**Selectivity and Safety**
- **Expression pattern**: basigin is expressed on BBB endothelium and also on immune cells (e.g., monocytes/dendritic cells); peripheral distribution may be **more restricted than TfR** in the sense of not being dominated by erythroid iron-uptake biology.
- **Physiology disruption risk**: basigin supports monocarboxylate transporter (MCT) expression and thus lactate/pyruvate transport. Key risk is **metabolic perturbation** (brain and/or peripheral), but the provided evidence frames this as potentially less directly catastrophic than iron uptake disruption (TfR) while still requiring dedicated chronic safety work.

**Translational feasibility**
- **Need for affinity tuning**: moderate–high because this is a receptor-targeting shuttle and (typically) a **bispecific**; requires balancing:
  - basigin binding (for transport)
  - therapeutic target binding (for efficacy)
- **Species cross-reactivity**: described as favorable (high conservation), supporting preclinical-to-clinical continuity.
- **Manufacturability/format complexity**: moderate because bispecific production/QC is required (heterodimer purity, chain pairing, etc.).

---

### 2.3 Comparison versus established targets (summary)
- **Vs TfR**:
  - FcRn approach avoids TfR-specific liabilities (iron biology, erythroid sink, strict monovalent low-affinity constraint) and can show much larger reported brain:serum ratio gains.
  - Basigin may avoid iron-specific risk but still needs trafficking validation and chronic metabolic/immune safety characterization.
- **Vs CD98hc**:
  - FcRn is simpler to manufacture (no bispecific), but CD98hc has reported long brain retention; FcRn may require more careful PK balancing due to systemic FcRn engagement.
  - Basigin is earlier in maturity than CD98hc in quantitative benchmarking.
- **Vs IGF1R**:
  - FcRn reduces dependence on receptor epitope conservation (engineering is on Fc), generally improving translational workflow.
  - Basigin is reported as more conserved, potentially simplifying translation relative to some IGF1R programs.

**Assumption/limitation (explicit)**
- The provided “data analysis output” indicates **no additional dataset-driven computation** was performed (“skipped”), so all comparisons here are grounded in the supplied literature-style evidence summary and its reported figures/claims; basigin quantitative performance remains a stated uncertainty.

---

## 3) Antibody-Based Drug Delivery Strategy Design

Below are execution-ready design strategies for the two selected approaches, including concrete steps, inputs/outputs, metrics, and caveats.

---

### 3.1 Strategy for FcRn-mediated BBB delivery: Fc-engineered monospecific IgG (no added shuttle arm)

**A. Shuttle formats**
- **Monospecific IgG** retained (therapeutic target specificity unchanged).
- BBB delivery enabled by **Fc substitutions** that increase **neutral pH FcRn binding** (per the provided evidence).

**B. Binding affinity strategies**
- Goal: increase FcRn binding at **pH 7.4** sufficiently to drive BBB transcytosis while not overly compromising:
  - pH-dependent recycling behavior
  - systemic half-life (avoid excessive clearance)
- Practical approach: screen a **panel of Fc variants** (e.g., variants described in the provided evidence such as M252Y and M252Y/Q309T) rather than assuming a single “best” mutation set.

**C. Proposed development pipeline (steps, inputs, outputs, metrics)**
1. **Input**: lead therapeutic antibody (IgG) against CNS target (e.g., amyloid/tau/synuclein/neuroinflammation target).
   - **Output**: a small Fc-variant library (WT Fc + multiple engineered Fc versions).
2. **Biophysical/developability screen**
   - **Inputs**: purified Fc-variant IgGs.
   - **Outputs**: stable, manufacturable candidates.
   - **Metrics**: expression yield, SEC aggregation %, thermal stability, general formulation stability.
3. **FcRn binding kinetics screen**
   - **Inputs**: Fc-variant IgGs; FcRn reagents.
   - **Outputs**: rank-ordered variants by FcRn binding at **pH 7.4** and **pH ~5.5–6**.
   - **Metrics**: KD/kon/koff at both pH conditions (method-agnostic: SPR/BLI acceptable).
4. **In vitro BBB transcytosis assay**
   - **Inputs**: human BBB model (e.g., iPSC-derived BMEC transwell), Fc-variants.
   - **Outputs**: transcytosis ranking.
   - **Metrics**:
     - TEER/permeability controls to confirm barrier integrity
     - apical→basolateral flux (percent dose transported; Papp if used)
     - control IgG baseline
5. **In vivo confirmation (rodent ± NHP)**
   - **Inputs**: top Fc-variants; dosing plan.
   - **Outputs**: brain exposure and brain:plasma ratio; PK/PD linkage if target has a measurable biomarker.
   - **Metrics**:
     - brain concentration and **brain:serum ratio**
     - time course (retention)
     - if available: capillary depletion to distinguish vascular vs parenchymal antibody (recommended)
     - target engagement readout (biomarker change consistent with payload mechanism; example provided evidence mentions anti-BACE1 lowering Aβ40)

**D. How this addresses established limitations**
- Avoids **TfR/CD98hc/IGF1R peripheral receptor sink biology** by not requiring an added receptor-targeting binding arm.
- Avoids **bispecific format complexity** (manufacturing and QC simpler).
- Can deliver large improvements in **brain:serum ratio** as reported in the provided evidence (tens-fold), exceeding typical fold-gains cited for many classical RMT shuttles.

**E. Key caveats/limitations**
- FcRn is ubiquitous: variants may increase exposure in other organs and alter systemic PK (shorter half-life for some variants). This must be explicitly optimized, not assumed.
- Because no BBB-unique receptor is targeted, BBB selectivity is an emergent property of endothelial FcRn trafficking and systemic PK—requires careful in vivo confirmation per therapeutic.

---

### 3.2 Strategy for Basigin (CD147)-targeted BBB delivery: bispecific antibody shuttle

**A. Shuttle formats**
Two practical, manufacturable options (to be evaluated head-to-head):
1. **Bispecific IgG (heterodimeric)**: one arm binds **basigin (CD147)** for BBB transport; the other arm binds the **therapeutic CNS target**.
2. **IgG–scFv fusion format (monovalent basigin binding)**: therapeutic IgG fused to an anti-basigin scFv/domain to enforce **monovalent** basigin engagement (a design pattern used for TfR shuttles in the provided evidence).

**B. Binding affinity strategies**
- Basigin arm:
  - Prioritize an affinity window that supports endocytosis/transcytosis without excessive intracellular trapping; the provided evidence notes that, consistent with RMT principles, **lower affinity can outperform at higher doses**, while higher affinity may help at tracer doses.
  - Therefore, generate a **small affinity panel** (e.g., higher-, medium-, lower-affinity variants) rather than committing upfront to a single affinity.
- Valency:
  - Evaluate **monovalent vs bivalent** basigin engagement empirically (basigin does not yet have the same well-defined “must be monovalent” rule as TfR).
- Optional: screen for **pH-dependent dissociation** (binds at pH 7.4, weaker at endosomal pH) as a potential lever to reduce intracellular trapping; this is a proven lever for TfR in the provided evidence, but **not yet established for basigin** (assumption to be tested, not taken as fact).

**C. Proposed development pipeline (steps, inputs, outputs, metrics)**
1. **Generate basigin-binding panel**
   - **Inputs**: basigin ectodomain and/or basigin-expressing cells.
   - **Outputs**: multiple anti-basigin binders spanning affinity/epitope diversity.
   - **Metrics**: cell-binding EC50; kinetic KD (pH 7.4 ± pH 5.5/6.0 characterization).
2. **Assemble bispecifics (and optionally IgG–scFv fusions)**
   - **Inputs**: anti-basigin candidates + therapeutic arm.
   - **Outputs**: bispecific constructs passing purity/stability thresholds.
   - **Metrics**: heterodimer purity, aggregation %, retained binding of both arms (≤~2-fold loss vs parent antibodies as a practical acceptance criterion).
3. **In vitro BBB transcytosis + trafficking**
   - **Inputs**: human BBB transwell model; labeled antibodies for imaging.
   - **Outputs**: ranked constructs + mechanistic confidence.
   - **Metrics**:
     - apical→basolateral transport vs non-targeted IgG control
     - intracellular localization markers consistent with productive routing (early/recycling vs late/lysosomal compartments), if assessed
4. **In vivo brain exposure confirmation**
   - **Inputs**: top constructs.
   - **Outputs**: brain uptake and evidence of parenchymal delivery.
   - **Metrics**:
     - brain concentration and brain:plasma ratio
     - capillary depletion (recommended) to confirm parenchymal vs vascular association
     - PK time course (does it resemble TfR-like transient uptake or show longer retention?)
5. **Safety focus areas (because basigin biology is not purely “inert”)**
   - **Inputs**: repeat-dose studies in relevant species.
   - **Outputs**: risk characterization.
   - **Metrics**:
     - endpoints related to monocarboxylate transporter-linked metabolism (as feasible)
     - immune cell phenotyping/cytokines (given immune expression noted in the provided evidence)

**D. How this addresses established limitations**
- Potentially reduces **TfR-specific** liabilities (iron pathway perturbation, erythroid sink).
- Compared with TfR’s narrow tuning constraints, basigin may offer a broader workable design space (still to be proven quantitatively).
- Strong species conservation (per provided evidence) can simplify translation relative to targets with poor cross-reactivity.

**E. Key caveats/limitations**
- Quantitative brain-delivery benchmarking is **less mature** than TfR/CD98hc in the provided evidence; a disciplined, data-driven optimization loop is required.
- Chronic effects of basigin engagement on lactate transport/metabolism and immune biology remain incompletely characterized in the provided evidence and must be treated as a central development risk.

---

### 3.3 Payload considerations (optional, applicable to both)
- Both approaches are compatible with:
  - standard IgG therapeutics (neutralizing or agonist/antagonist)
  - Fc-silent or effector-enabled designs depending on CNS target biology
  - fusions (enzymes, cytokines) or other biologic payloads, provided developability/PK remains acceptable
- The primary payload-related constraint is **required brain concentration** for efficacy: targets needing high parenchymal concentrations benefit most from the higher-efficiency approach (FcRn engineering), while targets tolerant of lower exposure or benefiting from specific cellular routing may be compatible with basigin shuttles after optimization.

---

### Final deliverable summary (what to do next)
- **Near-term, highest-confidence next-gen path** (per provided evidence): **FcRn Fc-engineering**, because it is modular, manufacturable, and associated with large reported increases in brain:serum ratios.
- **Second path with strong promise but key knowledge gaps**: **basigin (CD147) RMT bispecific shuttles**, prioritized if peripheral sink avoidance and receptor-targeted delivery are desired, with explicit early investments in trafficking validation and chronic safety de-risking.

---

# Red Team Review Feedback
## Reliability Score
- Score: 62
- Rationale: The report demonstrates competent synthesis of established BBB shuttle mechanisms and proposes two alternative strategies with reasonable scientific logic. However, critical weaknesses undermine confidence: (1) the FcRn-engineering approach conflates enhanced FcRn binding with BBB-specific transcytosis without adequately addressing that FcRn is ubiquitous and the mechanism for BBB selectivity remains poorly substantiated; (2) quantitative claims (e.g., "40–80× improvement in brain:serum ratio") are presented without primary source verification or critical evaluation of experimental conditions; (3) the basigin proposal acknowledges immaturity but still positions it as "most promising" despite admitting only "~1–4× improvement" with major knowledge gaps; (4) the report explicitly notes data analysis was "skipped," meaning all comparative assessments rest on unverified literature summaries.

## Critiques / Limitations / Risks (in priority order)

1. **FcRn mechanism conflation and selectivity gap**: The report treats enhanced neutral-pH FcRn binding as equivalent to enhanced BBB transcytosis, but FcRn is expressed throughout systemic endothelium. The mechanistic basis for why Fc engineering would preferentially enhance BBB transport over other vascular beds is not explained. The claim of "40–80× improvement in brain:serum ratio" requires scrutiny—such ratios could reflect altered systemic PK (faster clearance reducing serum levels) rather than absolute increases in brain uptake. This distinction is critical but unaddressed.

2. **Unverified quantitative claims**: Multiple specific figures are cited (e.g., "~131 nM" for trontinemab, "~150× in vitro," "~1–4× for basigin") without primary literature citations or critical evaluation of experimental contexts. The report acknowledges no independent data analysis was performed, yet presents these numbers as comparative benchmarks. This creates a significant reproducibility and verification risk.

3. **Basigin proposal lacks sufficient evidence threshold**: The report admits basigin shows only "~1–4× improvement" with "less mature" quantitative benchmarking, yet still selects it as one of two "most promising" candidates. This selection appears inconsistent with the stated evaluation criteria (efficiency, selectivity, feasibility). The rationale for prioritizing basigin over other emerging targets (e.g., LRP1, TMEM30A, or other candidates in the literature) is not provided.

4. **Safety assessment superficiality**: For both proposed strategies, safety concerns are acknowledged but not rigorously analyzed. The FcRn approach's impact on systemic IgG homeostasis and potential immunogenicity of Fc variants is mentioned but not evaluated. Basigin's role in MCT function and immune cell biology is flagged as a "development risk" without discussing existing preclinical data or dose-response relationships that might inform risk magnitude.

5. **Missing comparative framework for target selection**: The task explicitly requested comparison against established targets in terms of efficiency, selectivity/safety, and translational feasibility. While the report provides qualitative comparisons, it lacks a structured scoring or ranking system that would justify why FcRn and basigin were selected over other candidates. The exclusion rationale for alternative emerging targets is absent.

6. **Development pipeline lacks validation criteria**: The proposed pipelines include steps and metrics but omit critical go/no-go decision criteria. For example, what fold-improvement in brain:serum ratio would constitute success? What TEER threshold confirms barrier integrity? Without predefined success criteria, the pipelines are descriptive rather than actionable.

7. **Species cross-reactivity claims unsubstantiated**: The report asserts FcRn engineering has "strong overall feasibility" for cross-species translation and basigin has "high conservation," but provides no sequence identity data, binding cross-reactivity studies, or references to support these claims.

8. **Payload considerations underdeveloped**: The optional payload section is generic and does not address how payload properties (size, charge, stability) might interact with the proposed delivery mechanisms. For bispecific formats, the impact of payload on heterodimer assembly and stability is not discussed.

## Final Short Summary to Attach

This report provides a structured analysis of established BBB shuttle targets and proposes FcRn Fc-engineering and basigin-targeted bispecifics as next-generation approaches. However, the scientific rigor is compromised by: (1) mechanistic conflation of FcRn binding enhancement with BBB-selective transcytosis; (2) reliance on unverified quantitative claims without primary source evaluation; (3) selection of basigin despite acknowledged weak efficacy data; (4) superficial safety assessments; and (5) absence of structured comparative criteria for target selection. The development pipelines are descriptive but lack predefined success thresholds. The explicit acknowledgment that data analysis was "skipped" undermines confidence in the comparative conclusions. Reliability score: 62/100.

---

# Task
Revise the original answer based on the red-team feedback, ensuring the final output **satisfies the problem’s required answer format and all requirements**.

## Guidelines
- Incorporate revisions for critiques that are scientifically valid and relevant.
- Ensure internal consistency after all revisions.
- If the problem lists numbered requirements (e.g., "(1)...(5)"), **preserve the numbering/structure**.
- **Write in English.**

## Output Requirements
- Produce a complete revised answer.
- Do not include reviewer comments, response letters, or change logs.
- **Output only the revised report text.**
